Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
Share
Why It Matters
A big bank analyst thinks ResMed stock could be worth more money. Watch how the company grows its business and keeps customers happy.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.